logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Why Reata Pharmaceuticals Stock is Down Today. See Also: Important News from Exelixis

Reata Pharmaceuticals: Why its Stock Price is Down Reata Pharmaceuticals ( RETA ) announced that it has priced a public offering of 2,000,000 shares of its Class A common stock at a price to the public of $140.85 per share...

Read More

December 2, 2020

0

Illumina Acquisition of GRAIL: A Challenging Story That Boosted ILMN's Stock Price

Illumina Acquisition of GRAIL On September 21, 2020 , Illumina and GRAIL Inc. announced that they entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion, upon closing of the transaction. On...

Read More

March 31, 2021

0

Ionis and Alnylam Secured Their Future Prosperity

Ionis Pharmaceuticals Ionis Pharmaceuticals ( IONS ) announces a private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024. To read this news go to the original  content to download multimedia by clicking here .  During...

Read More

December 12, 2019

0

Amarin: The FDA Approves Vascepa for Lowering Cardiovascular Risk

From Amarin Amarin ( AMRN )  announced the U.S. FDA has approved a new indication and label expansion for Vascepa®  (icosapent ethyl) capsules. According to Amarin’s press release, with this label expansion approval, Vascepa has become the first and only FDA...

Read More

December 16, 2019

0

Gilead Sciences: FDA Fully Approves Trodelvy for Metastatic TNBC

Gilead Sciences is Granted FDA Approva l for Trodelvy® Gilead Sciences ( GILD ) , a company that has been granted more approvals than many are aware of except for the short analysts and their followers, today announced that the...

Read More

April 8, 2021

0

Regenxbio: Promising Results from RGX-121 Gene Therapy for Mucopolysaccharidosis Type II (MPS II)

Regenxbio Results from RGX-121 for MPSII Regenxbio ( RGNX ) announced interim data from Phase I/II trial of RGX-121 for Mucopolysaccharidosis Type II ( MPS II) . RGX-121  is designed to deliver the gene that encodes iduronate-2-sulfatase ( I2S )...

Read More

December 19, 2019

0

The FDA Granted Breakthrough Therapy Designation to vTv Therapeutics for Type 1 Diabetes Product TTP399

vTv Therapeutics Receives Breakthrough Therapy Designation for TTP399 vTv Therapeutics ( VTVT ) - a clinical-stage biopharmaceutical company focused on the development of oral treatments for type 1 diabetes, psoriasis, and other diseases, announced that the U.S. FDA has granted...

Read More

April 13, 2021

0

More fom the Prohost Portfolio

More from the Prohost Portfolio with Our Observations Gilead ( GILD ) has cash and new products reaching the market, and its agreement with Galapagos will soon bring another drug approval. We will tackle Gilead’s news and all the firms...

Read More

December 20, 2019

0

Compugen: More Highlighted News

Compugen Exclusive License Agreement with AstraZeneca In April 2018 Compugen ( CGEN ) and AstraZeneca ( AZN ) entered into an agreement by which Compugen provided an exclusive license to AstraZeneca for the development of bispecific and multi-specific antibody products...

Read More

December 23, 2020

0

Inovio DNA Vaccine Candidate INO-4800 has Promising Results. Read Also: Sutro Biopharma Good News

Inovio Pharmaceuticals Promising Results for INO-4800 for COVID-19 Inovio Pharmaceuticals ( INO ) announces promising results of a study focusing on the human immune responses induced by Inovio DNA vaccine candidate, INO-4800, against COVID-19, and variants of concern. The results...

Read More

April 15, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 108
  • 109
  • 110
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy